Abstract: Vascular alterations in diabetes cause or contribute to the etiology of microvascular complications such as nephropathy, neuropathy, and retinopathy. The endothelium controls the vascular smooth muscle tone through the production of vasodilator mediators such as nitric oxide, prostacyclin, and a still-elusive endothelium-derived hyperpolarizing factor (EDHF). Although EDHF is a prominent vasodilator, particularly in smaller arteries, little attention has been paid to the potential role of EDHF responses in diabetes. EDHF function may involve the participation of mediators, including several diffusible factors and non-diffusible factors, (e.g., conduction of hyperpolarization via myoendothelial gap junctions). Indeed, in several vessels, cyclic adenosine 3',5'-monophosphate (cAMP) facilitates EDHF responses by enhancing electrotonic conduction via gap junctions. It has been demonstrated that the alterations in EDHF relaxation seen in mesenteric arteries from diabetic rats may be attributable to an increase in phosphodiesterase3 (PDE3) activity, leading to a reduction in the action of cAMP, and moreover the activity of protein kinase A (PKA) is decreased in such arteries. Although an improvement in EDHF responses has not been, as yet, the subject of any direct pharmaceutical effort, increasing cAMP/PKA signaling (e.g., by inhibiting PDE3 activity) has potential as an interesting therapeutic target in diabetic microvascular disease.
INTRODUCTION
Vascular complications are the main causes of morbidity and mortality in patients with diabetes, and vascular alterations cause or contribute to the etiology of diabetic complications such as nephropathy, neuropathy, and retinopathy [1] [2] [3] [4] [5] [6] . Several lines of evidence suggest that endothelial dysfunction could play a key role in the development of both macro-and microangiopathy in patients with diabetes and in animal models of the disease [6] [7] [8] . Endothelial cells relax the tone of the underlying vascular smooth muscle cells by releasing a number of vasodilator substances, including nitric oxide (NO), prostacyclin (PGI 2 ), and an as-yet-elusive endothelium-derived hyperpolarizing factor (EDHF). A consistent finding in diabetic animal models is the presence of vascular endothelial dysfunction. This has been linked to elevated oxidative stress and is characterized by impaired NO-mediated endothelium-dependent relaxation, as noted for numerous individual vessels and vascular beds, including aorta, basilar and cerebral arteries, corpus cavernosum, and renal and mesenteric vascular beds [7, [9] [10] [11] [12] [13] [14] [15] [16] [17] . Studies in diabetic patients have revealed comparable deficits [6, 7] . Although NO has generally been considered to be the principal mediator of endothelium-dependent relaxations, it has become increasingly clear that NO-independent endotheliumderived relaxing factors may have also important roles to play in local vasomotor control. The contribution made by EDHF to relaxation is dependent on vessel size, its effects being more prominent in the smaller, physiologically more important arteries than in larger ones [18, 19] .
*Address correspondence to this author at the Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan; Tel./ Fax: +81-3-5498-5856; E-mail: kamata@hoshi.ac.jp As yet, little attention has been paid to the potential role of an impaired release or impaired action of EDHF in diabetes. Since small-vessel dysfunction (such as occurs in retinopathy, nephropathy, and neuropathy) is one of the major complications seen in diabetes, an impairment of EDHFmediated responses could make an important contribution to the mechanisms by which diabetes leads to vascular dysfunction. Thus, an improvement in EDHF signaling could be an interesting therapeutic target in cases involving diabetic vasculopathy.
In the present review, we will discuss (a) the possible mediators of EDHF activity, as well as their regulation and alterations in cellular signaling during diabetes, (b) the possible contribution of EDHF to the long-term vascular changes observed during diabetes, and (c) potential therapeutic modulation(s) of EDHF responses in diabetic states.
EDHF: NATURE AND PHYSIOLOGICAL IMPOR-TANCE
EDHF is defined as the non-NO/PGI 2 , endothelium-derived relaxing factor that mediates vascular smooth muscle hyperpolarization via a direct or indirect opening of vascular potassium (K + ) channels. It is important to recognize this distinction from NO and PGI 2 , each of which can also hyperpolarize smooth muscle in a highly tissue-dependent manner. Moreover, NO may be linked to the presence of active tone, as well as to the cellular mechanisms associated with the activation of vascular tone. Thus, a complete elimination of the synthesis and contribution of NO and PGI 2 must be achieved before it can be concluded that EDHF is involved in any given endothelium-dependent relaxation [20] .
EDHF-mediated responses--to any agonists, such as acetylcholine (ACh) or bradykinin (BK), that stimulate G- ]i is a crucial step [18, 21] (Fig. 1 ).
An increase in [Ca

2+
]i in endothelial cells leads to activation of Ca 2+ -activated K + channels and to membrane hyperpolarization (Fig. 1) [22] . Most likely, these effective channel toxins (apamin and charybdotoxin) act on sites located on endothelial cells, and their inhibitory effect is probably related to a decrease in the driving force for Ca 2+ entry, and hence to a reduction in the synthesis/release of EDHF [20] .
Despite numerous studies aimed at identifying a specific factor responsible for endothelium-dependent hyperpolarization, the putative mediator of the EDHF response may actually be one, or a combination, of a number of candidates. [18, 20, [23] [24] [25] [26] [27] [28] .
Pharmacological evidence indicates that EDHF is a significant component not only of agonist-induced vasodilation, but also of shear stress-induced vasodilation [20, 29, 30] . The contribution of NO is greater in the larger diameter arteries than in the resistance arteries, but EDHF has been found in both sizes of blood vessels [31] . Further in the coronary and renal vascular beds EDHF even plays a major role in conduit arteries [18] . Some years ago, Shimokawa et al. [19] demonstrated an inverse relationship between eNOS expression and vessel size in the rat (aorta versus proximal and distal mesenteric arteries), and they also reported a more negative resting membrane potential in the distal mesenteric resistance vessels, suggesting that a release of EDHF may influence their basal tone. Several studies have produced evidence of clear alterations in EDHF-mediated responses in various pathological conditions [8, 26, 27] , and also evidence of an important role for EDHF in anti atherogenic mecha- ]i, which leads to activation of Ca 2+ -dependent K + channels and membrane hyperpolarization. The hyperpolarization is conducted to the subadjacent smooth muscle cell (SMC) via myoendothelial gap junctions, and may subsequently spread through the vessel wall via the homocellular gap junctions that couple smooth muscle cells. The elevations in cytosolic Ca 2+ may also increase cAMP levels, thereby enhancing the electrical conductance of myoendothelial gap junctions. Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA), may contribute to endothelial hyperpolarization by opening store-operated channels and elevating [Ca 2+ ]i, as well as by having possible direct effects on K Ca channels. EETs may also stimulate the synthesis of cAMP by adenylyl cyclase (AC nisms [32] . Furthermore, the fact that certain therapeutic or adjutant interventions can restore EDHF responses in several pathophysiological states suggests that an improvement in these EDHF-mediated responses may contribute to the observed beneficial effects of such interventions (see below).
CONTACT-MEDIATED MECHANISM IN EDHF RE-SPONSE
There is considerable evidence that in some vascular beds, EDHF may not be a diffusible factor at all, but rather that the EDHF hyperpolarization initiated in the endothelial cells spreads through MEGJs to the underlying vascular smooth muscle cells (Fig. 1) [24] . Gap junctions are formed by the docking of two hemichannels (called connexons) at points of cell-to-cell contact, with each hemichannel being constructed from six connexin (Cx) protein subunits that traverse the cell membrane four times, thus exposing two extracellular peptide loops [24] . Several Cx subtypes have been identified in the vasculature, including Cx37, Cx40, Cx43, and Cx45 [24, 33] , and there is evidence that direct intercellular communication via gap junctions contributes to the EDHF phenomenon in conduit vessels. Indeed, AChinduced EDHF-type responses in a spectrum of rabbit arteries and/or veins, and rat mesenteric arteries can be inhibited (a) by synthetic peptides homologous to the Gap 26 or 27 domains of the first and second extracellular loops of Cx proteins, which interrupt intercellular communication in a Cx-specific fashion, and (b) by 18 -glycyrrhetinic acid (18 -GA), a lipophilic aglycone that disrupts gap-junction plaques [24, [34] [35] [36] [37] [38] [39] . A few years ago, an electrophysiological and electromicroscopic study revealed that endothelial and smooth muscle cells are electrically coupled via MEGJs in the rat mesenteric artery [40] . Moreover, in the mature rat femoral artery, which lacks MEGJs, shows no EDHF-mediated smooth muscle hyperpolarization of relaxation, despite the generation of a charybdotoxin + apamin-sensitive hyperpolarization in the endothelial cells [40] .
An accumulating body of evidence indicates that the second messenger cAMP regulates EDHF signaling in several vessels [24] . Observations that the EDHF-type relaxations evoked by ACh in the rabbit iliac artery is dependent on an elevation in the smooth muscle cAMP level and on phosphorylation events mediated by protein kinase A (PKA) suggest that even responses to agonists may not simply be mediated by passive electrotonic mechanisms [41] . Endogenous formation of cAMP may play an important role in the EDHF phenomenon because agonists such as ACh are capable of promoting endothelial synthesis of this nucleotide through a mechanism that is independent of the formation of prostanoids [41, 42] . Indeed, in rabbit ilio-femoral arteries the adenylyl cyclase (AC) inhibitor 2',5'-dideoxyadenosine (2',5'-ddA) markedly attenuates the subintimal smooth muscle hyperpolarization evoked by ACh, suggesting that cAMP generated within the endothelium plays an important role in facilitating electrical coupling via MEGJs during agonist-induced responses [43, 44] . This permissive role of cAMP is likely to explain the ability of 2',5'-ddA and PKA inhibition to attenuate EDHF-type relaxations in rabbit and rat arteries [37, 41, 43, 45] . Interestingly, cAMP accumulation can be suppressed by interrupting gap junctional communication using Cx-mimetic peptides or 18 -GA in the rabbit iliac artery [41] . Hence, it is possible that chemical signaling and gap junctions each contribute to the response to ACh because, in addition to conferring electrical continuity, gap junctions allow direct transfer of signaling molecules <1 kDa in size between coupled cells [24] . Furthermore, elevations in smooth muscle cAMP levels have been shown to facilitate electrotonic signaling within the vascular media, and thereby to amplify and prolong the transmission of ACh-induced hyperpolarizations to smooth muscle cells remote from the endothelium [43] . This mechanism is likely to contribute to the marked potentiation of EDHF-type relaxations reported in the presence of (a) the phosphodiesterase (PDE) inhibitor isobutylmethylxanthine (IBMX) or 8-bromo-cAMP in rabbit iliac arteries [37, 41, 43] , (b) IBMX in rat mesenteric arteries [39] , and (c) a cell-permeant cAMP analogue in rat renal arteries [46] . Thus, cAMP would seen to play an important role in the regulation of EDHF responses.
EDHF ACTIVITY IN DIABETIC STATES
Although the exact nature of the alterations in EDHF activity that in occur disease states remains unclear, there is emerging evidence to suggest that such alterations do occur both in disease states, such as hypertension and diabetes, and as a result of aging [7, 8, 26, 27, 33, 47] . Closer examination of the literature reveals a species segregation of the findings as follows: impaired EDHF activity in diabetic rats [15, 39, [48] [49] [50] [51] and diabetic humans [52] , but enhanced EDHF activity in diabetic mice [53] . For example, Fukao et al. [48] showed that both the amplitude and duration of the AChinduced hyperpolarization were significantly decreased in mesenteric arteries from diabetic rats. Inhibition of NO synthase did not affect the hyperpolarization response to ACh in mesenteric arteries from either control or diabetic rats, implying that the functional EDHF response in the rat mesenteric artery decreases as a result of diabetes. Furthermore, Wigg et al. [50] demonstrated a selective impairment of EDHF activity in smaller mesenteric resistance arteries, but not in femoral arteries, from STZ-induced type 1 diabetic rats, whereas NO-dependent responses studied in vitro were actually preserved. This strongly suggests that the impairment of endothelium-dependent relaxation seen in the diabetic mesenteric artery is attributable to the presence of a reduced EDHF-dependent response. These results are consistent with the finding of a more pronounced influence of EDHF in smaller vessels than in larger ones under normal conditions (see above). In diabetes, selective damage to the smaller resistance vessels, mediated via reduced EDHF activity, may provide a possible mechanism for the microvascular complications commonly observed in that disease. Further, the agonist-induced relaxation attributed to EDHF in human penile resistance arteries is greatly impaired in patients with type 1 and type 2 diabetes [52] . The factors mediating the impairment of EDHF responses seen in diabetes are currently under investigation (see below), but the fact that this impairment occurs in a range of vascular beds (including the epineural arterioles of the sciatic nerve, the mesenteric and carotid arteries, and renal arterioles) suggests that there may be a common mechanism [27] .
As mentioned above, there is emerging evidence to suggest that gap junctions may play a role in EDHF activity. Under high-glucose conditions, Cx43 expression and gap-junction activity have been found to be greatly reduced in microvascular endothelial cells [54] and in aortic endothelial and/or smooth muscle cells [55] . Furthermore, a disruption of gap-junction pathways has been observed in the retinal microvasculature of STZ-induced diabetic rats [56] . An upregulation of protein kinase C, which is known to be involved in diabetic complications [57, 58] , an alteration in Cx expression, and/or phosphorylation have been invoked to explain the changes in gap-junction function [55, 59, 60] .
A recent in vitro study in our laboratory [39] confirmed that in the mesenteric artery of STZ-induced diabetic rats, ACh-induced EDHF-type relaxation was impaired. Moreover, the EDHF response was sensitive to 18 -GA, a gap-junction inhibitor, and further investigation revealed increased PDE activity in the diabetic arteries, specifically PDE3, and reduced cAMP levels [39] . In that study, PDE inhibitors enhanced the EDHF-type relaxations in mesenteric arteries from both control and diabetic rats, but the augmentation was greater in the diabetics, such that maximal relaxation amplitude was then similar to control. Under normal conditions, cAMP appears to facilitate the spread of current through gap junctions, thus enabling the potentiation and transmission of EDHF-mediated hyperpolarization to regions electrically distant from the endothelium (see above section). Hence, it is possible that a reduction in cAMP activity via an increase in PDE could contribute to the impairment of EDHF-type relaxation that is observed in the resistance vessels of diabetic rats (Fig. 2) .
The intracellular level of cAMP is tightly regulated, both by control of its rate of synthesis (by ACs [61] [62] [63] , in response to extracellular signals) and by control of its rate of hydrolysis (by PDE) [64] [65] [66] . Following an intracellular elevation of cAMP, reversible phosphorylation of several protein substrates (including the gap-junction component Cx by PKA modulates many physiological processes [67] [68] [69] . It is known that PKA is activated by cAMP, and that it comprises two regulatory (R) and two catalytic (C) subunits, and several pieces of evidence indicate that PKA activity is determined by the expression-balance between the C and R subunits [67, 70] . In recent studies, we have demonstrated that the abnormal vascular relaxation responsiveness seen in STZ-diabetic rats may be attributable not only to increased PDE activity [39] , but also to decreases in PKA activity [71] and AC activity [72] . Possibly, the decreased PKA activity may result from an imbalance between PKA C and R subunit expressions [71] , and the decreased AC activity may result from reductions in AC5/6 expressions [72] . Taken together, the above results suggest that the cAMP/PKA signaling pathway could be intimately involved in the specific alteration of the EDHF-mediated response in the mesenteric artery that is seen in diabetic rats (Fig. 2) . Indeed, our recent study demonstrated that a selective PDE3 inhibitor could improve the EDHF response in the diabetic mesenteric artery (see below).
EDHF: A THERAPEUTIC TARGET
Several studies have suggested that impairments of EDHF-mediated responses may be present in disease states, indicating the potential for therapeutic interventions [26] . For instance, chronic treatment with an angiotensin converting-enzyme inhibitor, with an angiotensin-receptor antagonist, or with a diuretic normalizes EDHF-mediated responses in spontaneously hypertensive rats [26, 73] . Moreover, treatment with folate, with an aldose-reductase inhibitor, with calcium dobesilate (an angioprotective agent), with evening primrose oil (an -6 -linoleic acid-containing oil), or with trientine (a metal chelator) restores impaired EDHF-mediated responses in diabetic states [26, 52, [74] [75] [76] . In addition, dietary supplements and exercise have beneficial Fig. (2) . EDHF and potential new therapeutic targets in the diabetic state. cAMP facilitates EDHF-type relaxation by enhancing electrotonic conduction via gap junctions. The reduced EDHF-type relaxation present in the diabetic state may be attributable to an increase in PDE3 activity, leading to a reduction in the action of cAMP, and the reduced PKA activity may be due to an imbalance between the expressions of PKA catalytic and regulatory subunits. effects on EDHF responses [26] . However, the mechanisms underlying these drug-induced and adjutant-induced improvements in EDHF responses remain poorly understood. EDHF-mediated responses are clearly affected in a variety of pathological conditions, and the fact that the above therapeutic or adjutant interventions can restore these responses suggests that an improvement in EDHF-mediated responses might contribute to the observed beneficial effects of such interventions. Especially interesting is the possibility that an enhancement of EDHF-mediated responses might contribute to improvements in diabetic microvascular complications such as retinopathy, nephropathy, and neuropathy (since EDHF plays important roles in the microvasculature). In a recent study [45] , we noted that in STZ-induced diabetic mesenteric arteries: (a) treatment with cilostazol, a selective PDE3 inhibitor, improved ACh-, A23187-, and cyclopiazonic acid induced EDHF-type relaxations, (b) the AChinduced cAMP accumulation in mesenteric arteries was more sustained in cilostazol-treated than in cilostazol-untreated STZ rats, (c) the EDHF-type relaxation was significantly decreased by a PKA inhibitor in the cilostazol-treated group, but not in the cilostazol-untreated group, (d) cilostazol treatment improved both the relaxations induced by cAMP analogs and the PKA activity level, and (e) PKA C subunit (Cat ) protein was significantly decreased, but the R subunit RII was increased (and the latter effect was significantly diminished by cilostazol treatment). These results strongly suggest that cilostazol improves EDHF-type relaxations in STZ rats via an increase in cAMP/PKA signaling (Fig. 2) . Although cilostazol is used clinically in several diseases, such as peripheral artery disease [77] , the above study [45] (a) provided the first evidence of its potential as a therapeutic drug for the improvement of EDHF-mediated responses in diabetic states, and (b) strongly suggested that the reduced EDHF-mediated responses seen in diabetes may be improved by manipulation of the cAMP/PKA pathway (Fig. 2) . These findings should stimulate further interest in cilostazol as a potential therapeutic drug for use against diabetes-associated vascular disease, especially microvascular disease.
